Cover Image
市場調查報告書

多發性骨髓瘤的全球市場:產業分析與未來展望

Global Multiple Myeloma Market: Industry Analysis & Outlook 2016-2030

出版商 Koncept Analytics 商品編碼 366843
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
多發性骨髓瘤的全球市場:產業分析與未來展望 Global Multiple Myeloma Market: Industry Analysis & Outlook 2016-2030
出版日期: 2016年08月12日 內容資訊: 英文 53 Pages
簡介

本報告提供全球多發性骨髓瘤治療藥的市場相關分析,疾病的症狀和風險要素,相關市場趨勢預測 (初期/復發患者數等),主要的推動及阻礙市場要素,主要的治療藥以及市場規模,主要企業簡介等相關調查。

第1章 血液癌症:概要

  • 血液癌症的症狀
  • 血液癌症的治療方法
  • 血液癌症的種類
    • 白血病
    • 淋巴瘤

第2章 多發性骨髓瘤

  • 多發性骨髓瘤的特徵
    • 血球數低
    • 骨、鈣的問題
    • 感染疾病
    • 腎臟的問題
    • 單克隆性免疫球蛋白血症
    • 神經系統的症狀
  • 多發性骨髓瘤的風險要素
  • 發現多發性骨髓瘤的檢驗
    • 臨床檢驗
    • 影像診斷
  • 多發性骨髓瘤的治療方法

第3章 多發性骨髓瘤市場分析

  • 血液癌症的市場規模 (全球,以金額為準)
  • 多發性骨髓瘤的市場規模 (全球,以金額為準)
  • 初期治療的患者數 (全球)
  • 復發治療的患者數 (全球)

第4章 各地區市場

  • 美國
    • 多發性骨髓瘤的市場規模 (以金額為準)
    • 初期治療的患者數
    • 復發治療的患者數
  • 歐洲
  • 其他的國家 (RoW)

第5章 市場動態

  • 推動市場成長要素
    • 人口高齡化
    • 肥胖人口的增加
    • 醫療費的增加
    • 癌症治療藥的普及
  • 市場趨勢
    • 單株抗體的上市
    • 聯合治療的趨勢
    • 新加入廠商的空間
  • 市場課題
    • 價格高
    • 法律上的法規

第6章 競爭環境

  • 血液癌症產品市場預測:抗體的各類型
  • 多發性骨髓瘤的治療藥的認證,和各產品的作用機制

第7章 主要產品分析

  • Darzalex
    • Darzalex的銷售額的預測
  • 美國的Darzalex市場預測
    • 初期治療市場規模的預測
    • 復發治療市場規模的預測
  • 歐洲的Darzalex市場預測
  • 其他的國家 (RoW)的Darzalex市場預測
  • Isatuximab

第8章 企業簡介

  • Johnson & Johnson
    • 產業概要
    • 主要的財務指標
    • 產業策略
  • Roche Holding
  • Sanofi
  • Novartis

圖表一覽

目錄

Multiple Myeloma is a form of blood cancer. Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced. In myeloma, unusually large numbers of abnormal plasma cells gather in bone marrow and stop it from producing an important part of your immune system. Multiple myeloma is a cancer formed by malignant plasma cells. Multiple myeloma is characterized with low blood counts, bone and calcium problems, infections, kidney problems and nervous system symptoms. Usually the age factor is considered as the most prominent factor in multiple myeloma cases.

Multiple myeloma was considered to be a non-treatable disease but hopes have arrived with the approval of Darzalex which was a much awaited product and has shown positive results in the trials. Many other products are in the pipeline and will arrive after some time. Darzalex is an antibody with immense potential and was the first monoclonal antibody approved by the FDA for the treatment of heavily pretreated retreated multiple myeloma. More experiments have started to check out Darzalex in combinations to find out its effectiveness in case of other problems too.

The key factors which are anticipated to drive multiple myeloma market include increased penetration of cancer drugs, increase in ageing population, rising obese population and increase in healthcare expenditure. Some of the significant developments of this industry include upcoming new innovative products in the market, trend of combination therapies, and chance of new players. However, the challenge to be faced ahead is high price and legal regulations.

This report offers a comprehensive analysis of the Global Multiple Myeloma market. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global market is reined by few major players namely Johnson & Johnson, Roche Holding, Sanofi and Novartis. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

Table of Contents

1. Blood Cancer: An Introduction

  • 1.1. Symptoms of Blood cancer
  • 1.2. Treatment of Blood Cancer
  • 1.3. Types of Blood Cancer
    • 1.3.1. Leukaemia
    • 1.3.2. Lymphoma

2. Multiple Myeloma

  • 2.1. Characteristics of Multiple Myeloma
    • 2.1.1. Low Blood Counts
    • 2.1.2. Bone and Calcium Problems
    • 2.1.3. Infections
    • 2.1.4. Kidney Problems
    • 2.1.5. Monoclonal Gammopathy
    • 2.1.6. Nervous System Symptoms
  • 2.2. Risk Factors for Multiple Myeloma
  • 2.3. Tests to Find Multiple Myeloma
    • 2.3.1. Laboratory Tests
    • 2.3.2. Imaging Tests
  • 2.4. Treatment of Multiple Myeloma

3. Multiple Myeloma Market Analysis

  • 3.1. Global Blood Cancer Market by Value
  • 3.2. Global Multiple Myeloma Market Forecast by Value
  • 3.3. Global Forefront Treated Patients Forecast
  • 3.4. Global Reverted Treated Patients Forecast

4. Regional Markets

  • 4.1. The US
    • 4.1.1. The US Multiple Myeloma Market Forecast by Value
    • 4.1.2. The US Forefront Treated Patients Forecast
    • 4.1.3. The US Reverted Treated Patients Forecast
  • 4.2. Europe
    • 4.2.1. Europe Multiple Myeloma Market Forecast by Value
    • 4.2.2. Europe Forefront Treated Patients Forecast
    • 4.2.3. Europe Reverted Treated Patients Forecast
  • 4.3. Rest of World
    • 4.3.1. ROW Multiple Myeloma Market Forecast by Value
    • 4.3.2. ROW Forefront Treated Patients Forecast
    • 4.3.3. ROW Reverted Treated Patients Forecast

5. Market Dynamics

  • 5.1. Growth Drivers
    • 5.1.1. Ageing Population
    • 5.1.2. Rise in Obese Population
    • 5.1.3. Increase in Health Care Expenditure
    • 5.1.4. Increased Penetration of Cancer Drugs
  • 5.2. Trends
    • 5.2.1. Launch of Monoclonal Antibodies
    • 5.2.2. Trend of Combination Therapies
    • 5.2.3. Space for New Players
  • 5.3. Challenges
    • 5.3.1. High Price
    • 5.3.2. Legal Regulations

6. Competitive Landscape

  • 6.1. Blood Cancer Product Forecast by Type of Antibody
  • 6.2. Multiple Myeloma Therapies Approvals with Mechanism by Product

7. Key Product Analysis

  • 7.1. Darzalex
    • 7.1.1. Darzalex Sales Forecast by Value
  • 7.2. Darzalex Forecast in the US
    • 7.2.1. The US Darzalex Forefront Market Penetration Forecast
    • 7.2.2. The US Reverted Patients Market Penetration Forecast
  • 7.3. Darzalex Forecast in Europe
    • 7.3.1. Europe Darzalex Forefront Market Penetration Forecast
    • 7.3.2. Europe Reverted Patients Market Penetration Forecast
  • 7.4. Darzalex Forecast in ROW
    • 7.4.1. ROW Darzalex Forefront Market Penetration Forecast
    • 7.4.2. ROW Reverted Patients Market Penetration Forecast
  • 7.5. Isatuximab

8. Company Profiles

  • 8.1. Johnson & Johnson
    • 8.1.1. Business Overview
    • 8.1.2. Financial Overview
    • 8.1.3. Business Strategies
  • 8.2. Roche Holding
    • 8.2.1. Business Overview
    • 8.2.2. Financial Overview
    • 8.2.3. Business Strategies
  • 8.3. Sanofi
    • 8.3.1. Business Overview
    • 8.3.2. Financial Overview
    • 8.3.3. Business Strategies
  • 8.4. Novartis
    • 8.4.1. Business Overview
    • 8.4.2. Financial Overview
    • 8.4.3. Business Strategies

List of Charts

  • Types of Blood Cancer
  • Global Blood Cancer Market Forecast by Value (2015/2020)
  • Global Multiple Myeloma Market Forecast by Value (2016-2030)
  • Global Forefront Treated Patients Forecast (2016-2030)
  • Global Reverted Treated Patients Forecast (2016-2030)
  • The US Multiple Myeloma Market Forecast by Value (2016-2030)
  • The US Forefront Treated Patients Forecast (2016-2030)
  • The US Reverted Treated Patients Forecast (2016-2030)
  • Europe Multiple Myeloma Market Forecast by Value (2016-2030)
  • Europe Forefront Treated Patients Forecast (2016-2030)
  • Europe Reverted Treated Patients Forecast (2016-2030)
  • ROW Multiple Myeloma Market Forecast by Value (2016-2030)
  • ROW Forefront Treated Patients Forecast (2016-2030)
  • ROW Reverted Treated Patients Forecast (2016-2030)
  • Global Ageing Population (2006-2015)
  • Global Obese Population (2007-2015)
  • Global Healthcare Expenditure (2007-2015)
  • Darzalex Global Sales Forecast by Value (2016-2020)
  • The US Darzalex Forefront Market Penetration Forecast (2016-2030)
  • The US Reverted Patients Market Penetration Forecast (2016-2030)
  • Europe Darzalex Forefront Market Penetration Forecast (2016-2030)
  • Europe Reverted Patients Market Penetration Forecast (2016-2030)
  • ROW Darzalex Forefront Market Penetration Forecast (2016-2030)
  • ROW Reverted Patients Market Penetration Forecast (2016-2030)
  • Johnson & Johnson Sales by Segment (2015)
  • Johnson & Johnson Net Sales and Net Income (2011-2015)
  • Roche's Revenue Share by Segment (2015)
  • Roche's Revenue and Net Income (2011-2015)
  • Sanofi's Revenue Share by Segment (2015)
  • Sanofi's Revenue Share by Geography (2015)
  • Sanofi's Revenue and Net Income (2011-2015)
  • Novartis' Revenue Share by Business Segments (2015)
  • Novartis' Revenue Share by Geography (2015)
  • Novartis' Net Sales and Net Income (2011-2015)

List of Tables

  • Types of Monoclonal Antibodies
  • Multiple Myeloma Therapies with Mechanism by Product
  • Phase I/II Comparative Response Data in Darzalex and Isatuximab
Back to Top